Health
Affinity’s COVID-19 antibodies ready for manufacture for clinical trials – BSA bureau
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
Melbourne-based Affinity Biosciences Pty Ltd (Affinity) has lodged a pre-publication submission to the scientific journal, ‘mAbs’, detailing its results and observations relating to the discovery of potent antibodies against COVID-19. This can be found at the link,’Antib…
-
Noosa News18 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News16 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News22 hours agoBrisbane Broncos star Reece Walsh says punching friend in face ‘not a good look’
-
General14 hours agoDairy farmers devastated by floods across parts of New South Wales